These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11719746)

  • 21. Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it.
    Prescrire Int; 2007 Feb; 16(87):24-31. PubMed ID: 17323538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.
    Kamal RM; van Noorden MS; Wannet W; Beurmanjer H; Dijkstra BA; Schellekens A
    CNS Drugs; 2017 Jan; 31(1):51-64. PubMed ID: 28004314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic.
    Herold AH; Sneed KB
    J Am Board Fam Pract; 2002; 15(2):161-3. PubMed ID: 12002201
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use.
    Liechti ME; Kunz I; Greminger P; Speich R; Kupferschmidt H
    Drug Alcohol Depend; 2006 Feb; 81(3):323-6. PubMed ID: 16143455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse.
    Miró Ò; Galicia M; Dargan P; Dines AM; Giraudon I; Heyerdahl F; Hovda KE; Yates C; Wood DM; Liakoni E; Liechti M; Jürgens G; Pedersen CB; O'Connor N; Markey G; Moughty A; Lee C; O'Donohoe P; Sein Anand J; Puiguriguer J; Homar C; Eyer F; Vallersnes OM; Persett PS; Chevillard L; Mégarbane B; Paasma R; Waring WS; Põld K; Rabe C; Kabata PM
    Toxicol Lett; 2017 Aug; 277():84-91. PubMed ID: 28579487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
    Goodwin AK; Griffiths RR; Brown PR; Froestl W; Jakobs C; Gibson KM; Weerts EM
    Psychopharmacology (Berl); 2006 Nov; 189(1):71-82. PubMed ID: 17047936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known.
    van Noorden MS; van Dongen LC; Zitman FG; Vergouwen TA
    Gen Hosp Psychiatry; 2009; 31(4):394-6. PubMed ID: 19555805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamma-hydroxybutyrate detoxification by titration and tapering.
    de Jong CA; Kamal R; Dijkstra BA; de Haan HA
    Eur Addict Res; 2012; 18(1):40-5. PubMed ID: 22142784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.
    McDonough M; Kennedy N; Glasper A; Bearn J
    Drug Alcohol Depend; 2004 Jul; 75(1):3-9. PubMed ID: 15225884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone.
    Lenz D; Rothschild MA; Kröner L
    Ther Drug Monit; 2008 Dec; 30(6):755-61. PubMed ID: 18824955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Psychiatric disorders induced by drug dependence other than alcohol].
    Lejoyeux M; Mourad I; Ades J
    Encephale; 2000; 26(2):21-7. PubMed ID: 10858911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB.
    van Amsterdam J; Brunt T; Pennings E; van den Brink W
    Regul Toxicol Pharmacol; 2014 Nov; 70(2):507-13. PubMed ID: 25204614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol.
    Schneir AB; Ly BT; Clark RF
    J Emerg Med; 2001 Jul; 21(1):31-3. PubMed ID: 11399385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of anticonvulsants in barbiturate withdrawal.
    Okamoto M; Rosenberg HC; Boisse NR
    J Pharmacol Exp Ther; 1977 Aug; 202(2):479-89. PubMed ID: 560473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-center randomized study.
    Elsing C; Stremmel W; Grenda U; Herrmann T
    Am J Drug Alcohol Abuse; 2009; 35(3):189-92. PubMed ID: 19462303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [GHB--dangerous, addictive and uncontrollable "party drug"].
    Persson SA; Eriksson A; Hallgren N; Eklund A; Berkowicz A; Druid H
    Lakartidningen; 2001 Sep; 98(38):4026-31, 4033-5. PubMed ID: 11602959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gamma butyrolactone (GBL) withdrawal syndromes.
    Catalano MC; Glass JM; Catalano G; Burrows SL; Lynn WA; Weitzner BS
    Psychosomatics; 2001; 42(1):83-8. PubMed ID: 11161128
    [No Abstract]   [Full Text] [Related]  

  • 38. [First report of lethal gamma-hydroxybutyrate (GHB) intoxication after consumption of gamma-butyrolactone (GBL) in Lower Saxony].
    Fieguth A; Albrecht K; Weller JP; Kühnle R; Teske J
    Arch Kriminol; 2009; 223(1-2):45-51. PubMed ID: 19323150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Abuse of γ-hydroxybutyrate].
    Bramness JG; Haugland S
    Tidsskr Nor Laegeforen; 2011 Nov; 131(21):2122-5. PubMed ID: 22048208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial.
    Lingford-Hughes A; Patel Y; Bowden-Jones O; Crawford MJ; Dargan PI; Gordon F; Parrott S; Weaver T; Wood DM
    Trials; 2016 Sep; 17(1):472. PubMed ID: 27677382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.